Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles The IMF Is Raising the Alarm on Insurance Investments in Private Credit Michelle Celarier Valiant: ‘Not Only Did the Team Not Waiver — They Doubled Down’ Stephen Taub Fireside Chat: Why We’re Bullish About Asset-Based Private Credit Sponsored by Castlelake